12:00 AM
Nov 19, 2007
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avandia rosiglitazone regulatory update

FDA and GSK plan to supplement the existing boxed warning on the label of Avandia rosiglitazone to include new language noting that it has been associated with a potential increase in the risk of myocardial ischemic events such as angina or myocardial infarction. The risk was detected in a meta-analysis of short-term studies comparing Avandia to placebo, the label notes, also stating that 3 large, long-term studies comparing Avandia to other approved oral...

Read the full 343 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >